These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19711113)

  • 1. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.
    Outteryck O; Ongagna JC; Zéphir H; Fleury MC; Lacour A; Blanc F; Vermersch P; de Sèze J
    J Neurol; 2010 Feb; 257(2):207-11. PubMed ID: 19711113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
    Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
    Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
    Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The toronto observational study of natalizumab in multiple sclerosis.
    Krysko KM; O'Connor PW
    Can J Neurol Sci; 2011 May; 38(3):422-8. PubMed ID: 21515500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
    Weinstock-Guttman B; Galetta SL; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; O'Connor PW; Phillips JT; Polman C; Stuart WH; Lynn F; Hotermans C
    J Neurol; 2012 May; 259(5):898-905. PubMed ID: 22008873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
    Lublin FD; Cutter G; Giovannoni G; Pace A; Campbell NR; Belachew S
    Mult Scler Relat Disord; 2014 Nov; 3(6):705-11. PubMed ID: 25891549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
    Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
    Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
    Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
    Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.
    Belachew S; Phan-Ba R; Bartholomé E; Delvaux V; Hansen I; Calay P; Hafsi KE; Moonen G; Tshibanda L; Vokaer M
    Eur J Neurol; 2011 Feb; 18(2):240-245. PubMed ID: 20561044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of natalizumab on clinical and radiological disease activity in a French cohort of patients with relapsing-remitting multiple sclerosis.
    Melin A; Outteryck O; Collongues N; Zéphir H; Fleury MC; Blanc F; Lacour A; Ongagna JC; Berteloot AS; Vermersch P; de Sèze J
    J Neurol; 2012 Jun; 259(6):1215-21. PubMed ID: 22160375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
    Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
    Wiendl H; Butzkueven H; Kappos L; Trojano M; Pellegrini F; Paes D; Zhang A; Belachew S;
    PLoS One; 2016; 11(1):e0144834. PubMed ID: 26771747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study.
    Sousa L; de Sa J; Sa MJ; Cerqueira JJ; Martins-Silva A;
    Rev Neurol; 2014 Nov; 59(9):399-406. PubMed ID: 25342053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical baseline factors predict response to natalizumab: their usefulness in patient selection.
    Laroni A; Gandoglia I; Solaro C; Ribizzi G; Tassinari T; Pizzorno M; Parodi S; Baldassarre G; Rilla MT; Venturi S; Capello E; Sormani MP; Uccelli A; Mancardi GL
    BMC Neurol; 2014 May; 14():103. PubMed ID: 24885703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study 'TOPICS Greece'.
    Efthimios D; Georgios K; Antonia A; Rania G; Maria-Eleutheria E;
    Clin Drug Investig; 2021 Oct; 41(10):865-874. PubMed ID: 34427893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.